<DOC>
	<DOCNO>NCT00837876</DOCNO>
	<brief_summary>RATIONALE : Sorafenib erlotinib may stop growth tumor cell block enzymes need cell growth . Sorafenib may also stop growth tumor cell block blood flow tumor . Giving sorafenib together erlotinib may kill tumor cell . PURPOSE : This phase II trial study well give sorafenib together erlotinib work treat patient pancreatic cancer remove surgery .</brief_summary>
	<brief_title>Sorafenib Erlotinib Treating Patients With Pancreatic Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy sorafenib tosylate combination erlotinib hydrochloride patient unresectable pancreatic cancer . Secondary - To determine response rate patient treat regimen . - To determine progression-free survival patient treat regimen 4 month . - To evaluate safety profile regimen patient . - To evaluate change serum Ca 19-9 level baseline 8-week interval . - To evaluate plasma proteomic profile baseline 8 week correlate clinical parameter order identify potential prognostic predictive marker . - To analyze single-nucleotide polymorphism DNA obtain pretreatment blood sample evaluate toxicity response erlotinib hydrochloride . OUTLINE : Patients receive oral sorafenib tosylate twice daily oral erlotinib hydrochloride daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Serum sample collect baseline 8-week interval measure Ca 19-9 level , plasma buffy coat sample collect baseline week 8 proteomic assessment genotyping single-nucleotide polymorphism associate response toxicity erlotinib hydrochloride . After completion study treatment , patient follow every 3 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Microscopically confirm diagnosis pancreatic adenocarcinoma Unresectable disease No neuroendocrine tumor cystadenocarcinoma Measurable evaluable disease RECIST criteria No known brain metastasis Patients neurological symptom must undergo CT scan/MRI brain exclude brain metastasis PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN patient liver involvement ) Creatinine ≤ 1.5 time ULN INR &lt; 1.5 PT/PTT normal unless patient receive anticoagulation treatment Negative pregnancy test Not pregnant nursing Fertile patient must use effective barrier contraception , , least 6 month completion study treatment Able swallow whole pill No patient currently smoke No cardiac disease , include follow : NYHA class IIIIV congestive heart failure Unstable angina ( anginal symptom rest ) Newonset angina ( begin within past 3 month ) Myocardial infarction within past 6 month Cardiac ventricular arrhythmia require antiarrhythmic therapy No uncontrolled hypertension define systolic BP &gt; 150 mm Hg diastolic BP &gt; 90 mm Hg despite optimal medical management No arterial thrombotic embolic event ( e.g. , cerebrovascular accident , include transient ischemic attack ) within past 6 month No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 past 4 week No hemorrhage/bleeding event ≥ CTCAE grade 3 past 4 week No significant traumatic injury past 4 week No know untreated malabsorption problem ( e.g. , ulcerative colitis , Crohn 's disease ) No know HIV positivity chronic hepatitis B C No know suspect allergy sorafenib tosylate erlotinib hydrochloride No active clinically serious infection &gt; CTCAE grade 2 No serious nonhealing wound , ulcer , bone fracture No evidence history bleed diathesis coagulopathy ( except cancerrelated blood clot ) No dermatitis ≥ CTCAE grade 2 baseline No patient currently smoke PRIOR CONCURRENT THERAPY : No prior treatment antiangiogenics ( e.g. , bevacizumab , thalidomide , marimastat , interferon alfa , vatalanib , vandetanib , ZD6126 , sorafenib , semaxanib , sunitinib , axitinib ) No one line prior therapy metastatic disease More 4 week since prior major surgery open biopsy No concurrent strong CYP34A inhibitor inducer Concurrent warfarin heparin allow approval principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
</DOC>